Investigating NEU-411 for Early Parkinson's Disease
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)
Run by Neuron23 Inc. · NCT06680830 · Data updated 2026-11-12
This study is testing a new drug called NEU-411 to see if it can help people aged 50-80 with early Parkinson's Disease who have a specific genetic marker.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Neuron23 Inc. Industry-sponsored |
| Locations | 72 sites (Sun City, Arizona and 71 other locations) |
| Status | Recruiting |
| Started | January 17, 2025 |
| Main results expected | December 2027 |
| Study ends | June 2028 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT06680830 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women aged 50-80 with clinically established or probable Parkinson's Disease and LRRK2-driven PD.
✕Probably not a fit
Patients with secondary or atypical parkinsonian syndromes or uncontrolled diabetes may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 clinical trial aims to evaluate the efficacy and safety of NEU-411 in individuals aged 50-80 with early Parkinson's Disease who have elevated activity in the LRRK2 pathway, identified through a genetic test. Participants will be randomly assigned to receive either NEU-411 or a placebo daily for 52 weeks. The study will assess various outcomes, including the drug's pharmacokinetics and pharmacodynamics, compared to placebo. A follow-up visit will occur two weeks after the treatment period to monitor safety.
Why it matters
Potential benefit: If successful, this treatment could provide a targeted therapeutic option for patients with early Parkinson's Disease driven by LRRK2 activity.
How similar studies have gone: Other studies targeting the LRRK2 pathway have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 40-80 years at time of screening, inclusive 2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD) 3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx) 4. Modified Hoehn and Yahr (mH\&Y) of 1 to 2.5 Exclusion Criteria: 1. Secondary or atypical parkinsonian syndromes 2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) \>8% 3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening) Additional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.
Where it's running
-
Banner Sun Health Research Institute
Sun City, Arizona, United States Recruiting -
University of Arkansas
Little Rock, Arkansas, United States Recruiting -
Neuro-Pain Medical Center
Fresno, California, United States Recruiting -
University of California, Irvine
Irvine, California, United States Recruiting -
University of California, Los Angeles
Los Angeles, California, United States Recruiting -
Parkinson's Research Centers of America - Palo Alto
Palo Alto, California, United States Recruiting
Show 44 more locations
-
Sutter Neuroscience Institute
Sacramento, California, United States Recruiting -
University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States Recruiting -
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States Recruiting -
University of Florida
Gainesville, Florida, United States Recruiting -
Neurology One
Orlando, Florida, United States Recruiting -
USF Parkinson's & Movement Disorders Clinic
Tampa, Florida, United States Recruiting -
Emory University
Atlanta, Georgia, United States Recruiting -
Augusta University
Augusta, Georgia, United States Recruiting -
Northwestern Medical Group, Department of Neurology
Chicago, Illinois, United States Recruiting -
University of Kansas Medical Center
Kansas City, Kansas, United States Recruiting -
University of Kentucky
Lexington, Kentucky, United States Recruiting -
Ochsner Clinic Foundation
New Orleans, Louisiana, United States Recruiting -
University of Maryland
Baltimore, Maryland, United States Recruiting -
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States Recruiting -
Quest Research Institute
Farmington Hills, Michigan, United States Recruiting -
Struthers Parkinson Center
Golden Valley, Minnesota, United States Recruiting -
Cleveland Clinic
Las Vegas, Nevada, United States Recruiting -
University of New Mexico
Albuquerque, New Mexico, United States Recruiting -
Northwell Health
Manhasset, New York, United States Recruiting -
Icahn School of Medicine at Mount Sinai/Mount Sinai West
New York, New York, United States Recruiting -
Columbia University
New York, New York, United States Recruiting -
University of Rochester
Rochester, New York, United States Recruiting -
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States Recruiting -
The Ohio State University
Columbus, Ohio, United States Recruiting -
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, United States Recruiting -
Oregon Health & Science University (OHSU)
Portland, Oregon, United States Recruiting -
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States Recruiting -
Medical University of South Carolina
Charleston, South Carolina, United States Recruiting -
Vanderbilt University
Nashville, Tennessee, United States Recruiting -
Neurology Consultants of Dallas PA
Dallas, Texas, United States Recruiting -
Baylor College of Medicine
Houston, Texas, United States Recruiting -
The University of Texas Health Science Center at Houston
Houston, Texas, United States Recruiting -
Central Texas Neurology Consultants
Round Rock, Texas, United States Recruiting -
University of Utah Movement Division
Salt Lake City, Utah, United States Recruiting -
University of Virginia
Charlottesville, Virginia, United States Recruiting -
EvergreenHealth
Kirkland, Washington, United States Recruiting -
Inland Northwest Research
Spokane, Washington, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
Rambam Medical Center
Haifa, Israel Recruiting -
Shaare Zedek Medical Center
Jerusalem, Israel Recruiting -
Sheba Medical Center
Ramat Gan, Israel Recruiting -
Tel Aviv Medical Center
Tel Aviv, Israel Recruiting -
IRCCS Ospedale San Raffaele (HSR) - Dipartimento Di Neurologia
Milan, Italy Recruiting -
Universita Degli Studi Della Campania "Luigi Vanvitelli" - Azienda Ospedaliera Universitaria
Naples, Italy Recruiting
+22 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Fatta B Nahab, MD, FAAN FANA — Neuron23 Inc.
- Study coordinator: Fatta B Nahab, MD, FAAN, FANA
- Email: clinicaltrials@neuron23.com
- Phone: 650-228-2527
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mediterranean diet for people with Parkinson's disease
This study will try a Mediterranean diet to see if it helps motor and non-motor symptoms in people with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Detecting Parkinson's-related alpha-synuclein in colon tissue taken during routine colonoscopy
This will see if small extra colon tissue samples taken during a routine colonoscopy can find phosphorylated alpha-synuclein in people with Parkinson's disease or REM sleep behavior disorder.
-
Detecting phosphorylated alpha-synuclein in colon tissue to help diagnose Parkinson's
This study will test whether routine colonoscopy tissue samples from adults with Parkinson's show phosphorylated alpha-synuclein, a protein linked to the disease.
-
Community walking program for people with Parkinson's disease
This study tests a 6-month walking program for people with Parkinson's disease and their caregivers to see if it helps them stay active and connected with others.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.